



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Colmenar Viejo (Madrid), May 18, 2018

Pursuant to article 228 of the restated text of the Securities Market Law, we hereby inform you of the following **SIGNIFICANT EVENT**:

According to Board's decision adopted today, Pharma Mar has agreed to convene General Shareholders Meeting to be held at Instituto Ferial de Vigo (IFEVI), in Avda. del Aeropuerto, 772, Cotogrande -36318- Vigo, (Pontevedra), on June 28th, 2018 at 12:15 p.m. at second call since it is not predictable to meet the quorum required to hold the meeting at first call, scheduled for June 27th, 2018 at 12:15 p.m., at the same location. The matters that will be dealt with in said General Shareholders Meeting will be the following:

I. ITEMS SUBMITTED FOR VOTING

One.- *To review and, as the case may be, approve the Annual Financial Statements and Management Report of Pharma Mar, S.A. and its Consolidated Group for fiscal year 2017; the proposed allocation of earnings; and management by the Board of Directors during said period.*

Two.- *To reappoint the Statutory Auditors of the Company and its Consolidated Group.*

Three.- *Determination of the number of Directors. Appointment and re-election of members of the Board of Directors.*

3.1. *Determination of the number of Directors in ten.*

3.2. *Appointment as Director for the statutory period of four years of Mr. Valentín de Torres-Solanot del Pino, in the event that item 3.1 above is approved. Mr. Valentín de Torres-Solanot del Pino will have the category of Independent Director.*

3.3. *Re-election as Director for the statutory period of four years of Mr. José María Fernández Sousa-Faro, with the category of Executive Director.*

3.4. *Re-election as Director for the statutory period of four years of Mr. Pedro Fernández Puentes, with the category of Executive Director.*

3.5. *Re-election as Director for the statutory period of four years of Rosp Corunna Participaciones Empresariales, S.L., with the category of Proprietary Director.*

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com

3.6. *Re-election as Director for the statutory period of four years of Ms. Ana Palacio Vallelersundi, with the category of Independent Director.*

Four.- *To authorize the Board of Directors, with express power of substitution, to buyback treasury stock either directly or through Group companies.*

Five.- *To approve a Free of Charge Stock Ownership Plan for fiscal year 2019 aimed at officers and employees of the Group who, having an indefinite contract and receiving variable compensation, meet more than half of their targets set for fiscal year 2018, up to a total maximum limit of 500,000 shares in Pharma Mar, S.A., to be delivered in implementation of this Plan.*

Six.- *To submit the Annual Report on Compensation of Directors of Pharma Mar, S.A. for fiscal year 2017 to an advisory vote (Art. 541.4 of the Spanish Capital Corporations Law).*

Seven.- *To approve Pharma Mar, S.A.'s Directors' Compensation Policy for 2019-2021.*

Eight.- *To authorize the Board of Directors to interpret, remedy, supplement, implement, execute and develop the resolutions adopted by the General Meeting, both to record such resolutions in a public deed and to substitute the powers entrusted thereto by the General Meeting.*

II. INFORMATIONAL ITEMS

Nine.- *To report to the General Meeting, in accordance with the provisions of Article 528 of the Spanish Capital Corporations Law, regarding any amendments to the Board of Directors Regulations.*

It is also reported that the Board of Directors of Pharma Mar, S.A. has empowered its Chairman to determine the date of publication of the notice of call, it being foreseen in principle that said publication takes place in the coming days, at which time the aforementioned publication will be made available to the shareholders, the proposed resolutions that the Board will submit to the General Shareholders Meeting and other mandatory documentation related thereto, which will also be forwarded to the CNMV.

PHARMA MAR, S.A.